Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

Dr. Reddy's Laboratories reported a 1.5% year-over-year decline in consolidated revenue to $905 million for its fiscal second quarter ending September 30, 2026. However, strong demand in India and emerging markets helped maintain gross margins at 52.1%. Despite the slowdown, the company's underlying base business continued to grow double-digit, driven by expansion in key geographic markets and successful high-value generic launches.

Management addressed challenges in scaling active pharmaceutical ingredients (APIs), specifically for Semaglutide, a diabetes and weight-loss medication. Erez Israeli, the Chief Executive Officer, announced that this API scale-up hurdle has been resolved, allowing for supply reloads across Canada, Latin America, and Africa by November 2026.

The company is aggressively expanding its specialty portfolio, with Abatacept, a biosimilar biologic medication for rheumatoid arthritis, targeting a U.S. Food and Drug Administration decision by December 2026. Additionally, Dr. Reddy's is scaling its contract development and manufacturing organization (CDMO) segment, which reached $100 million in trailing 12-month revenue. The company remains focused on advancing Abatacept and other complex generics as they progress through regulatory review processes.

Underlying performance across core geographies remained steady, with brand acquisitions and supply chain efficiencies supporting operating margins. Dr. Reddy's leverages strong local distribution networks and expanding biosimilar capabilities to defend market share while monitoring raw material costs and maintaining cost discipline across operating units.

The company remains committed to delivering consistent growth and sustainable margins, investing in future growth drivers such as growth peptides, biosimilars, consumer health, and innovation.